NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: The New Rules of Biotech Book Release and Content
The New Rules of Biotech is now available in hardcover and audiobook formats, offering founders and investors a guide to building biotech companies in the current market.
The book is a guide for building biotech companies in the current market, covering topics like choosing between a platform and an asset, selecting affordable modalities, raising seed rounds based on milestones, and using non-dilutive capital strategically.
The author is David Craig, a biotechnology founder and longtime industry operator who founded a preclinical biotech company partly due to a family connection to a rare genetic muscle disease.
The biotech playbook from 2021 no longer works because capital is more expensive, the FDA bar has moved, and the Inflation Reduction Act has changed drug economics. The book provides an operating manual for building companies under these new conditions.
The book is available in hardcover ($29.99), paperback ($21.99), Kindle ($11.99), and audiobook on Google Play. Links are provided for purchase on Amazon and Google Play.
The book is written for founders, institutional investors, board members, and operators. Each chapter includes takeaways for operators and a separate section for investors and advisors.
It covers choosing between a platform and an asset, selecting affordable modalities, raising seed rounds based on milestones, using non-dilutive capital strategically, IND-enabling work, CMC, clinical decisions, term sheets, boards, business development, and exits like acquisitions and IPOs.
Each chapter closes with takeaways for operators and a separate read for investors and advisors, so the same material serves both sides of the table.
Craig founded his company partly due to a family connection to RYR-1 related congenital muscular dystrophy, and this connection runs through the book, arguing that biotech company building carries a responsibility beyond returns.